333 related articles for article (PubMed ID: 36875096)
1. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.
Frederico SC; Darling C; Bielanin JP; Dubinsky AC; Zhang X; Hadjipanayis CG; Kohanbash G
Front Immunol; 2023; 14():1057567. PubMed ID: 36875096
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
4. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Sanders S; Debinski W
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
[TBL] [Abstract][Full Text] [Related]
6. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract][Full Text] [Related]
8. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
Ser MH; Webb MJ; Sener U; Campian JL
J Immunother Precis Oncol; 2024 May; 7(2):97-110. PubMed ID: 38721406
[TBL] [Abstract][Full Text] [Related]
10. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
11. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
14. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):266-269. PubMed ID: 35976319
[TBL] [Abstract][Full Text] [Related]
16. T lymphocyte-targeted immune checkpoint modulation in glioma.
Kelly WJ; Giles AJ; Gilbert M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051289
[TBL] [Abstract][Full Text] [Related]
17. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
Bouffet E; Larouche V; Campbell BB; Merico D; de Borja R; Aronson M; Durno C; Krueger J; Cabric V; Ramaswamy V; Zhukova N; Mason G; Farah R; Afzal S; Yalon M; Rechavi G; Magimairajan V; Walsh MF; Constantini S; Dvir R; Elhasid R; Reddy A; Osborn M; Sullivan M; Hansford J; Dodgshun A; Klauber-Demore N; Peterson L; Patel S; Lindhorst S; Atkinson J; Cohen Z; Laframboise R; Dirks P; Taylor M; Malkin D; Albrecht S; Dudley RW; Jabado N; Hawkins CE; Shlien A; Tabori U
J Clin Oncol; 2016 Jul; 34(19):2206-11. PubMed ID: 27001570
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T; Hemadou A; Romero Garmendia I; Saleh M
Front Immunol; 2020; 11():585616. PubMed ID: 33154756
[TBL] [Abstract][Full Text] [Related]
20. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
